Onconetix Inc.

Onconetix Inc. is a commercial-stage biotechnology company specializing in the research, development, and commercialization of innovative therapeutics, diagnostics, and services targeted at oncology and men's health. The company’s portfolio includes Entadfi, an FDA-approved oral combination therapy of finasteride and tadalafil, designed to treat benign prostatic hyperplasia, a common prostate disorder affecting men. Another key offering is Proclarix, a proprietary, protein-based blood diagnostic test that aids in the screening and diagnosis of prostate cancer, particularly for patients with indeterminate Prostate Specific Antigen (PSA) results. Onconetix engages in strategic partnerships, such as its agreement with LabCorp, to expand the reach and impact of its diagnostic technologies. Founded in 2018 and headquartered in Cincinnati, Ohio, Onconetix plays a significant role in advancing precision medicine and improving outcomes in urological and oncology care, supporting clinicians and patients with sophisticated solutions across the care continuum.